Please login to the form below

Not currently logged in
Email:
Password:

Celgene’s CEO Mark Alles is appointed as chairman

He succeeds Bob Hugin who is retiring from the pharma firm

Executive chairman Bob Hugin has decided to retire from Celgene after 19 years of service and will step down from the board of directors effective 5 February.

Hugin initially joined Celgene as its chief financial officer and then subsequently became chief operating officer and chief executive officer.

His successor will be Celgene’s current chief executive officer Mark Alles, who will remain as CEO along side his new position as the chairman of the board of directors.

Alles has been with Celgene since 2004, holding roles such as chief operational officer and executive vice president, global head of haematology and oncology.

Michael Casey, Celgene’s lead independent director, said: “Mark is a tremendous leader and the best person to guide Celgene into its next phase of significant growth.

“Through his strategic leadership as CEO, Celgene has advanced and expanded its portfolio of potentially life-changing medicines.”

6th February 2018

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...